Early and sustained non-HDL-c target achievement after MI

Jessica Schubert

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
MinuteCE®
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
0.75 program credits
- Ulrich Laufs, MD, PhD
0.75 program credits
MinuteCE®
Clinical choices in managing LDL-c: Where do novel therapies fit in?
0.75 credits 4 episodes
- Prof. Kausik Ray, MBChB, MD, MPhil
- Julia Brandts, MD
- Pasquale Perrone-Filardi, MD, PhD
- Ulrich Laufs, MD, PhD
0.75 credits 4 episodes
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
MinuteCE®
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
0.75 program credits
- Pasquale Perrone-Filardi, MD, PhD
0.75 program credits
MinuteCE®
Clinical scenarios addressing residual risk in ASCVD: Understanding the role of triglycerides and EPA
0.50 credits 3 episodes
- Prof. Alberto Zambon MD, PhD, FAHA
- Prof. Kausik Ray, MBChB, MD, MPhil
- Azfar Zaman, MD
0.50 credits 3 episodes